Markets

Insider Trading

Hedge Funds

Retirement

Opinion

5 Best Medical Stocks to Invest In According to Billionaires

In this article, we will list the 5 Best Medical Stocks to Invest In According to Billionaires. Please visit 12 Best Medical Stocks to Invest In According to Billionaires if you would like to see the extended list and the methodology behind it.

5. Danaher Corporation (NYSE:DHR)

Number of Billionaire Holders: 31

Danaher Corporation (NYSE:DHR) is one of the best medical stocks to invest in according to billionaires. RBC Capital resumed coverage of Danaher Corporation (NYSE:DHR) with an Outperform rating on May 14, setting a price target of $200. The firm told investors in a research note that it sees the company’s growth recovering with an improvement in the bioprocess market. It further added that factors like the lapping of “idiosyncratic headwinds”, a sustained bioprocess rebound, and end market improvement put the company’s 6% revenue growth target within reach for 2027.

For reference, in its financial results for fiscal Q1 2026, Danaher Corporation (NYSE:DHR) reported net earnings of $1.0 billion, or $1.45 per diluted common share. Revenues for the quarter rose 3.5% year-over-year to $6.0 billion, while non-GAAP core revenue grew 0.5% year-over-year. The company also reported that operating cash flow was $1.3 billion, while non-GAAP free cash flow was $1.1 billion.

Danaher Corporation (NYSE:DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services, making it a significant diagnostics stock. It operates through Diagnostics, Biotechnology, Life Sciences, and Environmental and Applied Solutions.

4. Intuitive Surgical, Inc. (NASDAQ:ISRG)

Number of Billionaire Holders: 31

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the best medical stocks to invest in according to billionaires. Intuitive Surgical, Inc. (NASDAQ:ISRG) announced on May 21 several recent and upcoming innovations, which included enhancements across da Vinci 5 and its supporting ecosystem, advancements designed to enhance product and instrument security and reliability, and extended‑use Force Feedback instruments.

Management stated that over 100 updates and user experience improvements will be available to users soon, including telepresence enhancements, Da Vinci 5 surgeon console mobile login, and SimNow 2 targeted learning. Additional features are also expected to be available in the United States later this year, including digital ruler, Surgeon-initiated tool eject, and Multi-arm targeting. These are subject to regulatory clearance.

For reference, in its financial results for fiscal Q1, Intuitive Surgical, Inc. (NASDAQ:ISRG) reported that worldwide procedures for da Vinci and Ion combined grew around 17% compared to fiscal Q1 2025, with Da Vinci procedures growing approximately 16%, and Ion procedures growing approximately 39%. Revenue for the quarter came up to $2.77 billion, up 23% compared to $2.25 billion in the prior year period. The company also reported that it placed 431 da Vinci surgical systems, compared with 367 in fiscal Q1 2025.

Intuitive Surgical, Inc. (NASDAQ:ISRG) has an elaborate ecosystem of services and products that provide robotic-assisted surgical solutions and invasive care. Its products include the Ion Endoluminal and the Da Vinci Surgical systems.

3. Eli Lilly and Company (NYSE:LLY)

Number of Billionaire Holders: 31

Eli Lilly and Company (NYSE:LLY) is one of the best medical stocks to invest in according to billionaires. Eli Lilly and Company (NYSE:LLY) received a rating update from Truist on May 1, with the firm maintaining a Buy rating on the shares with a price target of $1,281. It stated that the company’s retatrutide Phase 3 clinical trial data in obesity announced the same day marks a new benchmark for anti-obesity medications, showing that patients on retatrutide high dose of 12 mg saw 28.3% weight loss at 80 weeks and 30.3% at 104 weeks. The firm told investors in a research note that it believes this will support retatrutide approval and use in patients that are not adequately served with existing incretin options.

The same day, Wolfe Research also maintained an Outperform rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,350. It told investors in a research note that the company’s reported pivotal phase 3 results for retatrutide further bolster its GLP-1 franchise leadership and differentiation in obesity therapeutics.

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.

2. Boston Scientific Corporation (NYSE:BSX)

Number of Billionaire Holders: 36

Boston Scientific Corporation (NYSE:BSX) is one of the best medical stocks to invest in according to billionaires. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in Las Vegas, it updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, inflation kicking up post-war, ACA, and utilization worries, and “data centers over healthcare”.

In another development, Argus cut the price target on Boston Scientific Corporation (NYSE:BSX) to $95 from $115 on April 27, reaffirming a Buy rating on the shares. The rating update came after the company’s fiscal Q1 earnings and guidance cut, with the firm telling investors in a research note that the stock has recently underperformed the broader market. However, it added that the company remains well-positioned in high-growth areas such as cardiovascular, electrophysiology, and neuromodulation, with the management setting more achievable objectives by cutting its outlook. Argus believes that Boston Scientific Corporation’s (NYSE:BSX) price weakness creates a buying opportunity.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

1. UnitedHealth Group Incorporated (NYSE:UNH)

Number of Billionaire Holders: 37

UnitedHealth Group Incorporated (NYSE:UNH) is one of the best medical stocks to invest in according to billionaires. UnitedHealth Group Incorporated (NYSE:UNH) reported on May 11 that Optum Rx announced a new pharmacy care model that changes the pricing and delivery of pharmacy benefits by replacing the traditional approach of prices set by manufacturers or prescription volume with a transparent, fee‑based structure that is offered to every Optum Rx PBM customer. Management stated that the model is specialized to fully align incentives with patients and plan sponsors. The new approach would allow Optum Rx clients a pricing structure with monthly, clearly defined fees per member, independent of manufacturers’ list prices or prescription volume, which would help eliminate spread pricing and similar practices.

In a separate development, UnitedHealth Group Incorporated (NYSE:UNH) received a rating update from Goldman Sachs on May 1, with the firm adding the stock to its US Conviction list. Goldman Sachs has a Buy rating on the shares with a price target of $435 and believes that the company is nearing the bottom of its underwriting cycle for Medicare Advantage, which presents 40% of its business. The rating update came as part of the firm’s monthly update.

UnitedHealth Group Incorporated (NYSE:UNH) provides healthcare coverage, data consultancy, and software services. It operates through the OptumRx, OptumInsight, OptumHealth, and UnitedHealthCare segments.

While we acknowledge the potential of UNH to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than UNH and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.